Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

Covid19 Clinical Trial

— PANCOLIN  

Official title:

Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04543006
• Other study ID #: EssaiClinique_PANCOLIN
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 8, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: September 2020
• Source: University Hospital, Grenoble
• Contact: Olivier Epaulard, MD,PhD
• Phone: 0033476765291
• Email: oepaulard[@]chu-grenoble.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.

The investigators will explore patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.

The investigators will determine whether this persistance varies according to

• the severity of the Covid-19

• a treatment by steroids during the covid-19. This will help to anticipate whether a second wave of infection is possible in a non-naive population.

Description:

Covid-19 is associated with the onset of anti-SARS-CoV-2 antibodies; in a majority of patients, neutralizing antibodies are detected. However, the long-term persistence of such protective antibodies is not known.

The investigators will explore adult patients with a proven Covid-19 (positive PCR) 6 and 12 months after the diagnosis to determine whether neutralizing antibodies are still detected.

The investigators will determine whether this persistance varies according to

• the severity of the Covid-19 (3 groups: no oxyegn therapy; oxygen therapy of less than 3L/min; oxygen therapy of 3L/min or more)

• a treatment by steroids during the covid-19. Immunocompromised patients will be excluded.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 170
• Est. completion date: December 31, 2021
• Est. primary completion date: September 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• positive SARS-CoV-2

Exclusion Criteria:

• age under 18

• immunocompromised at the onset of Covid-19

Related Conditions & MeSH terms

• Covid19

Intervention

Diagnostic Test:
• serology
blood sample of 10 ml twice (6 and 12 months after the Covid-19)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	anti-SARS-CoV-2 neutralizing antibody titers	Titer in plamsa of neutralizing anti-SARS-CoV-2 antibody	1 day